ArticleDiabetes2024
Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses.
Article in Diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Identification and expression validation of key genes of Xiaozhengtongluo formula in the treatment of diabetic nephropathy by Mendelian randomization.Functional & integrative genomics · 2026Article
- Pathology-Anchored Biomarker Research Progress for the Early Diagnosis of Diabetic Kidney Disease: From Pathological Association to Early Validation.Biomedicines · 2026Review
- Causal Association Between Plasma Proteins and Pericarditis: A Mendelian Randomization Study With Therapeutic Target Identification.Mediators of inflammation · 2026Article
- Immunoproteomic mediators of diabetic peripheral neuropathy: causal insights from Mendelian randomization and single-cell validation.Frontiers in immunology · 2026Article
- Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches.World journal of diabetes · 2025Article
- Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies.Renal failure · 2025Review
- Causal Associations of Cardiovascular Proteins and Diabetic Nephropathy Revealed by Mediation and Phenome-Wide Mendelian Randomization.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Exploring the Proteomic Signature of Diabetic Nephropathy: Implications for Early Diagnosis and Treatment.Life (Basel, Switzerland) · 2025Article
- Circulating Plasma Proteins as Biomarkers for Immunotherapy Toxicity: Insights from Proteome-Wide Mendelian Randomization and Bioinformatics Analysis.Biomedicines · 2025Article
- Therapeutic Targets for Sepsis: Multicenter Proteome-Wide Analyses and Experimental Validation.Journal of proteome research · 2025Article
- Proteome-wide Mendelian randomization and colocalization analysis identify therapeutic targets for stroke.BMC neurology · 2025Article
- The Omics-Driven Machine Learning Path to Cost-Effective Precision Medicine in Chronic Kidney Disease.Proteomics · 2025Review
- The Identification of Biomarkers and Therapeutic Targets for Diabetic Kidney Disease by Integrating the Proteome with the Genome.Biomedicines · 2025Article
- Untargeted metabolomic and proteomic analysis implicates SIRT2 as a novel therapeutic target for diabetic nephropathy.Scientific reports · 2025Article
- Therapeutic Potential of hucMSC-EVs in Diabetic Kidney Disease via Regulating the miR-146b-5p/Merlin/YAP Axis.Stem cells international · 2025Article
- Mitochondrial Dysfunction and Immune Cell Infiltration in Diabetic Kidney Disease: A Mendelian Randomization and Multiomics Study.Mediators of inflammation · 2025Article
- Genetically Prioritized Plasma Proteins as Candidate Therapeutic Targets for Dry Age-Related Macular Degeneration.Journal of ophthalmology · 2025Article
- Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.The Journal of international medical research · 2024Article
- Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.Communications biology · 2024Article
- Therapeutic targets for age-related macular degeneration: proteome-wide Mendelian randomization and colocalization analyses.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
At present, safe and effective treatment drugs are urgently needed for diabetic kidney disease (DKD). Circulating protein biomarkers with causal genetic evidence represent promising drug targets, which provides an opportunity to identify new therapeutic targets. Summary data from two protein quantitative trait loci studies are presented, one involving 4,907 plasma proteins data from 35,559 individuals and the other encompassing 4,657 plasma proteins among 7,213 European Americans. Summary statistics for DKD were obtained from a large genome-wide association study (3,345 cases and 2,372 controls) and the FinnGen study (3,676 cases and 283,456 controls). Mendelian randomization (MR) analysis was conducted to examine the potential targets for DKD. The colocalization analysis was used to detect whether the potential proteins exist in the shared causal variants. To enhance the credibility of the results, external validation was conducted. Additionally, enrichment analysis, assessment of protein druggability, and the protein-protein interaction networks were used to further enrich the research findings. The proteome-wide MR analyses identified 21 blood proteins that may causally be associated with DKD. Colocalization analysis further supported a causal relationship between 12 proteins and DKD, with external validation confirming 4 of these proteins, and TGFBI was affirmed through two separate group data sets. These results indicate that targeting these four proteins could be a promising approach for treating DKD, and warrant further clinical investigations. ARTICLE HIGHLIGHTS:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.